243 related articles for article (PubMed ID: 26658871)
1. Mitochondrial Superoxide Contributes to Hippocampal Synaptic Dysfunction and Memory Deficits in Angelman Syndrome Model Mice.
Santini E; Turner KL; Ramaraj AB; Murphy MP; Klann E; Kaphzan H
J Neurosci; 2015 Dec; 35(49):16213-20. PubMed ID: 26658871
[TBL] [Abstract][Full Text] [Related]
2. Amyloid β-induced impairments in hippocampal synaptic plasticity are rescued by decreasing mitochondrial superoxide.
Ma T; Hoeffer CA; Wong H; Massaad CA; Zhou P; Iadecola C; Murphy MP; Pautler RG; Klann E
J Neurosci; 2011 Apr; 31(15):5589-95. PubMed ID: 21490199
[TBL] [Abstract][Full Text] [Related]
3. Administration of CoQ10 analogue ameliorates dysfunction of the mitochondrial respiratory chain in a mouse model of Angelman syndrome.
Llewellyn KJ; Nalbandian A; Gomez A; Wei D; Walker N; Kimonis VE
Neurobiol Dis; 2015 Apr; 76():77-86. PubMed ID: 25684537
[TBL] [Abstract][Full Text] [Related]
4. Lack of UBE3A-Mediated Regulation of Synaptic SK2 Channels Contributes to Learning and Memory Impairment in the Female Mouse Model of Angelman Syndrome.
Sun J; Liu Y; Hao X; Baudry M; Bi X
Neural Plast; 2022; 2022():3923384. PubMed ID: 36237484
[TBL] [Abstract][Full Text] [Related]
5. Reversal of impaired hippocampal long-term potentiation and contextual fear memory deficits in Angelman syndrome model mice by ErbB inhibitors.
Kaphzan H; Hernandez P; Jung JI; Cowansage KK; Deinhardt K; Chao MV; Abel T; Klann E
Biol Psychiatry; 2012 Aug; 72(3):182-90. PubMed ID: 22381732
[TBL] [Abstract][Full Text] [Related]
6. Deleting a UBE3A substrate rescues impaired hippocampal physiology and learning in Angelman syndrome mice.
Sell GL; Xin W; Cook EK; Zbinden MA; Schaffer TB; O'Meally RN; Cole RN; Margolis SS
Sci Rep; 2021 Sep; 11(1):19414. PubMed ID: 34593829
[TBL] [Abstract][Full Text] [Related]
7. The Angelman syndrome ubiquitin ligase localizes to the synapse and nucleus, and maternal deficiency results in abnormal dendritic spine morphology.
Dindot SV; Antalffy BA; Bhattacharjee MB; Beaudet AL
Hum Mol Genet; 2008 Jan; 17(1):111-8. PubMed ID: 17940072
[TBL] [Abstract][Full Text] [Related]
8. Mitochondrial dysfunction in CA1 hippocampal neurons of the UBE3A deficient mouse model for Angelman syndrome.
Su H; Fan W; Coskun PE; Vesa J; Gold JA; Jiang YH; Potluri P; Procaccio V; Acab A; Weiss JH; Wallace DC; Kimonis VE
Neurosci Lett; 2011 Jan; 487(2):129-33. PubMed ID: 19563863
[TBL] [Abstract][Full Text] [Related]
9. Impaired hippocampal plasticity and altered neurogenesis in adult Ube3a maternal deficient mouse model for Angelman syndrome.
Mardirossian S; Rampon C; Salvert D; Fort P; Sarda N
Exp Neurol; 2009 Dec; 220(2):341-8. PubMed ID: 19782683
[TBL] [Abstract][Full Text] [Related]
10. Adenosine A
Moreira-de-Sá A; Gonçalves FQ; Lopes JP; Silva HB; Tomé ÂR; Cunha RA; Canas PM
Neurobiol Dis; 2020 Dec; 146():105137. PubMed ID: 33049319
[TBL] [Abstract][Full Text] [Related]
11. Ube3a reinstatement identifies distinct developmental windows in a murine Angelman syndrome model.
Silva-Santos S; van Woerden GM; Bruinsma CF; Mientjes E; Jolfaei MA; Distel B; Kushner SA; Elgersma Y
J Clin Invest; 2015 May; 125(5):2069-76. PubMed ID: 25866966
[TBL] [Abstract][Full Text] [Related]
12. JNK signaling activation in the Ube3a maternal deficient mouse model: its specific inhibition prevents post-synaptic protein-enriched fraction alterations and cognitive deficits in Angelman Syndrome model.
Musi CA; Agrò G; Buccarello L; Camuso S; Borsello T
Neurobiol Dis; 2020 Jul; 140():104812. PubMed ID: 32087286
[TBL] [Abstract][Full Text] [Related]
13. The mitochondria-targeted antioxidant MitoQ prevents loss of spatial memory retention and early neuropathology in a transgenic mouse model of Alzheimer's disease.
McManus MJ; Murphy MP; Franklin JL
J Neurosci; 2011 Nov; 31(44):15703-15. PubMed ID: 22049413
[TBL] [Abstract][Full Text] [Related]
14. Mitochondria-targeted antioxidant (MitoQ) ameliorates age-related arterial endothelial dysfunction in mice.
Gioscia-Ryan RA; LaRocca TJ; Sindler AL; Zigler MC; Murphy MP; Seals DR
J Physiol; 2014 Jun; 592(12):2549-61. PubMed ID: 24665093
[TBL] [Abstract][Full Text] [Related]
15. Adult
Rotaru DC; van Woerden GM; Wallaard I; Elgersma Y
J Neurosci; 2018 Sep; 38(37):8011-8030. PubMed ID: 30082419
[TBL] [Abstract][Full Text] [Related]
16. Maternal Loss of Ube3a Impairs Experience-Driven Dendritic Spine Maintenance in the Developing Visual Cortex.
Kim H; Kunz PA; Mooney R; Philpot BD; Smith SL
J Neurosci; 2016 Apr; 36(17):4888-94. PubMed ID: 27122043
[TBL] [Abstract][Full Text] [Related]
17. Dysbindin-1 loss compromises NMDAR-dependent synaptic plasticity and contextual fear conditioning.
Glen WB; Horowitz B; Carlson GC; Cannon TD; Talbot K; Jentsch JD; Lavin A
Hippocampus; 2014 Feb; 24(2):204-13. PubMed ID: 24446171
[TBL] [Abstract][Full Text] [Related]
18. Ketone ester supplementation attenuates seizure activity, and improves behavior and hippocampal synaptic plasticity in an Angelman syndrome mouse model.
Ciarlone SL; Grieco JC; D'Agostino DP; Weeber EJ
Neurobiol Dis; 2016 Dec; 96():38-46. PubMed ID: 27546058
[TBL] [Abstract][Full Text] [Related]
19. Towards a therapy for Angelman syndrome by targeting a long non-coding RNA.
Meng L; Ward AJ; Chun S; Bennett CF; Beaudet AL; Rigo F
Nature; 2015 Feb; 518(7539):409-12. PubMed ID: 25470045
[TBL] [Abstract][Full Text] [Related]
20. Hypersociability in the Angelman syndrome mouse model.
Stoppel DC; Anderson MP
Exp Neurol; 2017 Jul; 293():137-143. PubMed ID: 28411125
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
